IL212962A0 - Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases - Google Patents
Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseasesInfo
- Publication number
- IL212962A0 IL212962A0 IL212962A IL21296211A IL212962A0 IL 212962 A0 IL212962 A0 IL 212962A0 IL 212962 A IL212962 A IL 212962A IL 21296211 A IL21296211 A IL 21296211A IL 212962 A0 IL212962 A0 IL 212962A0
- Authority
- IL
- Israel
- Prior art keywords
- modulation
- treatment
- autoimmune diseases
- inflammatory response
- chronic inflammatory
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101150081923 IL4 gene Proteins 0.000 title 1
- 230000012085 chronic inflammatory response Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801601 | 2008-11-17 | ||
| PCT/DK2009/050304 WO2010054667A1 (en) | 2008-11-17 | 2009-11-17 | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL212962A0 true IL212962A0 (en) | 2011-07-31 |
Family
ID=41510516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL212962A IL212962A0 (en) | 2008-11-17 | 2011-05-17 | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8546321B2 (enExample) |
| EP (1) | EP2365983B1 (enExample) |
| JP (1) | JP5750373B2 (enExample) |
| CN (1) | CN102216323B (enExample) |
| AU (1) | AU2009316076B2 (enExample) |
| BR (1) | BRPI0921717A2 (enExample) |
| CA (1) | CA2743394C (enExample) |
| ES (1) | ES2620437T3 (enExample) |
| IL (1) | IL212962A0 (enExample) |
| NZ (1) | NZ592943A (enExample) |
| RU (1) | RU2542375C2 (enExample) |
| WO (1) | WO2010054667A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2989085T3 (es) | 2011-01-18 | 2024-11-25 | Bioniz Therapeutics Inc | Composiciones para modular la actividad de citoquinas gamma-c |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| DK3277722T3 (da) * | 2015-04-02 | 2021-10-11 | Intervet Int Bv | Antistoffer mod canin interleukin-4 receptor alpha |
| HUE056544T2 (hu) | 2015-10-09 | 2022-02-28 | Bioniz Llc | Gamma-C-citokin aktivitás modulálása |
| KR20240142577A (ko) * | 2017-04-07 | 2024-09-30 | 바이오니즈 테라퓨틱스, 아이엔씨. | 감마-c-사이토카인 활성의 안정한 조절자 |
| KR102095284B1 (ko) * | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
| EP3530320B1 (en) | 2018-02-27 | 2023-11-15 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Novel il-4-/il-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases |
| CN110746507B (zh) * | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
| KR20220005082A (ko) | 2019-05-03 | 2022-01-12 | 바이오니즈, 엘엘씨 | 탈모 및 탈모 관련 문제증상 치료를 위한 감마-c-사이토카인 신호전달 효과 조절 |
| EP4419130B1 (en) * | 2022-01-05 | 2025-05-28 | Serodus ApS | Il-4 derived peptides for use in the treatment of obesity |
| JP7634138B1 (ja) | 2022-04-29 | 2025-02-20 | セロダス アンパーツセルスケープ | 糖尿病性腎症の治療における使用のためのｉｌ－４由来ペプチド断片 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05503088A (ja) * | 1989-11-21 | 1993-05-27 | ザ ユニバーシティー オブ メルボルン | 抗炎症用の組成物及び方法 |
| NZ236511A (en) * | 1989-12-20 | 1993-02-25 | Schering Corp | Polypeptides containing sequences from residues 61 to 82 or 104 to 129 of human il-4 or subsequences thereof; antibodies and pharmaceutical compositions |
| US6337072B1 (en) * | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
| EP1156823B1 (en) * | 1999-02-12 | 2008-10-29 | The Scripps Research Institute | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US20030056244A1 (en) * | 2000-05-02 | 2003-03-20 | Ning Huang | Feed additive compositions and methods |
| FR2838444B1 (fr) * | 2002-04-10 | 2016-01-01 | Neovacs | Nouveaux peptides et leur application en therapeutique |
| WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
| JP2007537989A (ja) * | 2003-10-16 | 2007-12-27 | アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 安定化ペプチド |
-
2009
- 2009-11-17 EP EP09764175.7A patent/EP2365983B1/en active Active
- 2009-11-17 WO PCT/DK2009/050304 patent/WO2010054667A1/en not_active Ceased
- 2009-11-17 RU RU2011121971/10A patent/RU2542375C2/ru not_active IP Right Cessation
- 2009-11-17 AU AU2009316076A patent/AU2009316076B2/en not_active Ceased
- 2009-11-17 CA CA2743394A patent/CA2743394C/en active Active
- 2009-11-17 US US13/127,574 patent/US8546321B2/en active Active
- 2009-11-17 BR BRPI0921717A patent/BRPI0921717A2/pt not_active IP Right Cessation
- 2009-11-17 ES ES09764175.7T patent/ES2620437T3/es active Active
- 2009-11-17 CN CN200980145907.4A patent/CN102216323B/zh not_active Expired - Fee Related
- 2009-11-17 NZ NZ592943A patent/NZ592943A/xx not_active IP Right Cessation
- 2009-11-17 JP JP2011535880A patent/JP5750373B2/ja active Active
-
2011
- 2011-05-17 IL IL212962A patent/IL212962A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009316076B2 (en) | 2015-11-19 |
| BRPI0921717A2 (pt) | 2018-10-09 |
| US20110300148A1 (en) | 2011-12-08 |
| CN102216323B (zh) | 2016-08-03 |
| CN102216323A (zh) | 2011-10-12 |
| CA2743394A1 (en) | 2010-05-20 |
| WO2010054667A1 (en) | 2010-05-20 |
| EP2365983B1 (en) | 2016-12-28 |
| CA2743394C (en) | 2018-01-02 |
| ES2620437T3 (es) | 2017-06-28 |
| EP2365983A1 (en) | 2011-09-21 |
| JP5750373B2 (ja) | 2015-07-22 |
| AU2009316076A1 (en) | 2010-05-20 |
| NZ592943A (en) | 2012-09-28 |
| RU2011121971A (ru) | 2012-12-27 |
| RU2542375C2 (ru) | 2015-02-20 |
| JP2012508698A (ja) | 2012-04-12 |
| US8546321B2 (en) | 2013-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL212962A0 (en) | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases | |
| IL210810B (en) | Peptides to treat pain and/or inflammation | |
| IL259547B (en) | Isolated protein and preparations containing it for use in the treatment of disorders caused by il-1 | |
| IL211034A0 (en) | Treatment of autoimmune and inflammatory disease | |
| IL186749A0 (en) | Dihydrothienopyrimidines for the treatment of inflammatory diseases | |
| IL211930A (en) | Peptides and nonsense for their use in preventing cell adhesion | |
| IL223667B (en) | 4a100s antibodies and medical uses thereof | |
| PL2496596T3 (pl) | Peptydy terapeutyczne | |
| GB0904044D0 (en) | The treatment of inflammatory disorders and pain | |
| ZA200908989B (en) | Enhancement of the efficacy of therapeutic proteins | |
| IL215054A (en) | Peptides for the treatment of neurodegenerative diseases | |
| GB2460181B (en) | Depsipeptides and their therapeutic use | |
| GB2460178B (en) | Depsipeptides and their therapeutic use | |
| IL216199A (en) | A peptide containing the sequence ednimvtfrnqasr | |
| ZA201100019B (en) | Variant hhip1 protein and methods and uses thereof | |
| GB0724953D0 (en) | Methods of peptide modification | |
| PL2555790T3 (pl) | ZASTOSOWANIE LECZNICZE ß2-MIKROGLOBULINY | |
| EP2254901A4 (en) | THERAPEUTIC PEPTIDES | |
| GB2460180B (en) | Depsipeptides and their therapeutic use | |
| PL2265279T3 (pl) | Zastosowanie nonapeptydu pat w leczeniu chorób autoimmunologicznych | |
| HK1152532A (en) | Treatment of autoimmune and inflammatory disease | |
| GB0817330D0 (en) | The treatment of inflammatory disorders and pain | |
| GB0803397D0 (en) | The treatment of inflammatory disorders and pain | |
| GB0820986D0 (en) | The treatment of inflammatory disorder and pain | |
| GB0809319D0 (en) | The treatment of puritus |